Grant of Warrants

June 15, 2026

Announcement no. 13

                                                                        

Grant of Warrants

15, 2026, (GLOBE NEWSWIRE) – The Board of Directors of BioPorto A/S (“BioPorto” or the “Company”) (CPH:BIOPOR) has today decided to issue a total of 1,200,000 warrants to members of the Company’s Senior Leadership Team.

Each warrant entitles the holder the right to subscribe for one share in BioPorto at an exercise price of DKK 1.15 per share. The warrants are issued in accordance with section 18 a of the Articles of Association.

The warrants vest in three equal annual tranches over a 3-year period. For each tranche, half of the warrants vest subject to continued employment and half vest subject to achievement of certain KPI’s tied to the Company’s revenue performance in the period 2026-2028. The warrants are otherwise subject to the Company’s incentive warrant program as included in Appendix 1 of the Company’s Articles of Association. The warrants include conditions on claw-back in case of e.g., erroneous financial information and provisions on accelerated vesting in case of e.g., a takeover bid and/or business combinations.

Detailed terms of the new and existing warrants can be found in the Articles of Association on www.bioporto.com under Investor Relations> Governance> Company Articles.

The theoretical market value of the newly issued warrants is DKK 529,103. The calculation is based on the Black-Scholes formula using an interest rate of 2.32% and the historical volatility of BioPorto A/S’ shares over 36 months calculated to 54.18%.

To receive BioPorto’s Company Announcements, Press Releases, Newsletters and other business relevant information, please sign up on https://bioporto.com/investor-contact/.

Investor Relations Contacts

Klaus Juhl Wulff, Investor Relations, BioPorto A/S, [e-mail], C: [phone]

About BioPorto

BioPorto is an in vitro diagnostics company focused on saving patients’ lives and improving their quality of life with actionable kidney biomarkers – tools designed to help clinicians make changes in patient management. The Company leverages its expertise in assay development to create a pipeline of novel and compelling products that focus on conditions where there is significant unmet medical need, and where the Company’s tests can help improve clinical and economic outcomes for patients, providers, and the healthcare ecosystem.

Schreibe Deinen Kommentar